Results-c-Ki-ras mutations were detected in 10 (50%) of 20 patients with pancreatic cancer, in one (9%) of 11 with cholangiocarcinoma, and in two (33%) of six patients with metastatic biliary obstruction (primary tumours: colon and prostate). C-Ki-ras mutations were not detected in the controls and patients with ampullary cancer. Conclusions-The sensitivity of this test is too low at 50% to recommend its use clinically, but with refinement has potential as a diagnostic marker for pancreatic cancer.
Most (over 90%) of pancreatic adenocarcinomas harbour mutations in codon 12 of the c-Ki-ras gene. '2 Recent studies have reported the presence of the oncogene in pancreatic juice3 and pancreatic duct brushings4 in over 90% of patients with pancreatic cancer, suggesting that the oncogene might be useful as a diagnostic marker of pancreatic cancer. Pancreatic juice is, however, relatively difficult to obtain endoscopically, and performing brushings of the pancreatic duct adds significantly to procedure time of endoscopic retrograde cholangiopancreatography (ERCP). Bile is easy to collect endoscopically, particularly when a stent is inserted. Obstructive jaundice is a frequent presentation ofpancreatic cancer, and these patients are generally managed by ERCP, which has the advantage of being a combined diagnostic and therapeutic modality. The aim of our study was to determine whether c-Ki-ras mutations can be detected in bile from patients with biliary strictures caused by pancreatic cancer and other biliary tumours, with a view to developing bile c-Ki-ras mutations as a non-invasive diagnostic marker of pancreatic cancer.
Methods
Bile was collected from a total of 89 subjects referred for ERCP. Demographic details are shown in the table. These 89 subjects included 47 controls (20 patients with pancreatic cancer, 11 with cholangiocarcinoma, five with ampullary cancer, and six with biliary obstruction caused by metastases). The control group consisted of 30 patients with bile duct calculi (11 patients with a normal biliary tree, one patient with a postoperative biliary leak, and three with benign biliary strictures caused by chronic pancreatitis, Mirizzi syndrome, and iatrogenic post-cholecystectomy bile duct injury). The patient with chronic pancreatitis had previously undergone a cystjejunostomy for pseudocyst following alcoholic pancreatitis. In the 20 patients with pancreatic cancer, a tissue diagnosis was achieved in four only: three by laparotomy and the other by ascitic fluid cytology. Percutaneous fine-needle aspiration biopsy was unsuccessful in four cases, the material obtained being insufficient for diagnosis, consisting of necrotic tissue and red blood cells. The diagnosis of pancreatic cancer in the remaining 16 was based on radiological (computed tomography/ERCP) appearances, and clinical follow up: all 20 patients have died, with a median survival of six months (range one to 16 months). Four patients underwent surgery: one had a Whipple's procedure, two had palliative biliary by-pass procedures, and the other a gastrojejunostomy. Of the 11 patients with cholangiocarcinoma, tissue diagnosis was achieved in one only, by laparoscopic biopsy of omental deposits. In the remaining 10 patients, diagnosis was based on typical radiological appearances (all had hilar strictures) and clinical follow up: nine of these 10 patients have died, with a median survival of five months (range one to 18 months). One patient is alive at 19 months following stenting, and none underwent surgery. In the five patients with ampullary cancer, tissue diagnosis was achieved in all by endoscopic biopsy. In the six patients with metastatic biliary obstruction, Detection of c-Ki-ras mutations in bile 1 2 3 4 5 6 7 8 9 10 11 12
stNl digest: the samples are run in pairs of digested and undigested products (even-numbered lanes contain digested products). Lanes 2, 6 and 10 contain samples with c-Kiras codon 12 mutations. Lanes 1 and 12, 100 base pair marker.
the primary tumours were colon (n = 3), oesophagus (n = 1), stomach (n = 1), and prostate (n = 1). Results c-Ki-ras codon 12 mutations were detected in 10 (50%) of the 20 patients with pancreatic cancer, in one (9%) of the 11 patients with cholangiocarcinoma, and in two (33%) of the six patients with metastatic biliary obstruction (primary tumours: colon and prostate) (table) . Mutations were not detected in any of the controls or the patients with ampullary cancer.
Discussion c-Ki-ras mutations were detected in patients with malignant disease (or presumed malignant disease) only. In relation to pancreatic cancer the sensitivity (50%) was disappointing, given the high prevalence (>90%) of c-Ki-ras mutations in pancreatic cancer. There are two possible explanations for the low sensitivity: (1) low cellularity in some bile samples, and (2) 
